Clin2
NCT06652529Possibly a fitNot yet recruiting

Testing a new drug AROG4-01 for advanced solid tumors

Solid Tumors (Phase 1)MesotheliomaColorectal CarcinomaOvarian CancerNSCLC (Advanced Non-small Cell Lung Cancer)

Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.

This trial tests a new drug called AROG4-01 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to find the right dose and see if the drug can help shrink or slow tumor growth.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
35 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older with an advanced solid tumor (a cancer that has spread or cannot be removed).
  • You have tried standard treatments and they are no longer working, or you cannot have standard treatment.
  • You are able to take care of yourself (ECOG performance status 0-2) and expected to live at least 12 weeks.
  • Your blood counts and organ function (kidney, liver, bone marrow) are within acceptable ranges.
  • You have not had any cancer therapy (chemotherapy, radiation, major surgery) in the last 4 weeks, and any side effects from past treatment are mild.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03917043Recruiting· Phase 1
Testing a new targeted drug for ALK or ROS1 lung cancers

This Phase 1 trial tests APG-2449, a new drug, in people with advanced solid tumors—especially certain lung cancers that have ALK or ROS1 gene fusions. Because it’s an early safety-and-dose study, it may help learn how well the drug works and what doses are safe.

Beijing, Beijing Municipality
NCT07049458Not yet recruiting· Phase 1/Phase 2
Testing a new drug for advanced solid tumors

This trial tests a new drug called CHO-A04 for people with advanced solid tumors that have not responded to standard treatments or who cannot take them. It aims to see if the drug is safe and effective.

Taipei
NCT07438782Recruiting· Phase 1
Study of a new drug for advanced solid tumors

This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.

Philadelphia, Pennsylvania
NCT06717750Recruiting· Phase 1
Study of a new drug for advanced solid tumors

This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.

Beijing, Beijing Municipality
NCT06718621Recruiting· Phase 1
Testing a new drug for advanced solid tumors

This trial tests an experimental drug called BL-M08D1 for people with solid tumors that have spread or cannot be removed by surgery and have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.

Shanghai, Shanghai Municipality
NCT06440005Recruiting· Phase 1
Testing AGX101 for advanced solid tumors

This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.

Los Angeles, California

Hear when a new Solid Tumors (Phase 1) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.